Rebecca Nally
Optometrist · Rochester, NYNPI 1407875347
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.8%), food and beverage and education — rather than concentrated in one kind of arrangement. Coopervision Inc. accounts for 65.3% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $1,043 and has fallen 88.1% since, to $124 in 2025.
Across 22 payments — averaging $82.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coopervision Inc.$1K
- Bausch & Lomb Americas Inc.$173
- Shire North American Group Inc$115
- Biotissue Holdings Inc.$112
- Kala Pharmaceuticals, Inc.$84
- Johnson & Johnson Vision Care, Inc.$67
- plus $80 from 3 others
What the payments were for
- Consulting fees$1,00055%
- Food & beverage$80644%
- Education$181%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coopervision Inc. | 6 | $1,191 |
| Bausch & Lomb Americas Inc. | 4 | $173 |
| Shire North American Group Inc | 1 | $115 |
| Biotissue Holdings Inc. | 1 | $112 |
| Kala Pharmaceuticals, Inc. | 1 | $84 |
| Johnson & Johnson Vision Care, Inc. | 4 | $67 |
| Alcon | 2 | $33 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $29 |
| ABB Con-cise Optical Group LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Biofinity Contact Lens$1,000
- INFUSE$125
- XIIDRA$115
- Prokera$112
- AmnioGraft$112
- AmnioGuard$112
- MyDay Contact Lens$108
How this compares
$1,824 in reported general payments places this provider in the 75th percentile of 2,743 optometrist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 12 | $22,241 |
| Cyclosporine | 13 | $12,096 |
| Travoprost | 12 | $1,563 |
| Latanoprost | 149 | $1,520 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 28 | $1,050 |
| Prednisolone Acetate | 17 | $664 |
| Timolol Maleate | 47 | $486 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 27 | $299 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 20 | $216 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Rochester
- Vadim GuyRochester$31K
- Lisa ChuteRochester$9K
- Roy KlineLake Katrine$822K
- Susan ResnickNew York$463K
- Murray FingeretHewlett$374K
- Albert MorierSlingerlands$347K
- Denise WhittamNew York$343K
- Justin BazanBrooklyn$303K
- Jennifer TsaiNew York$275K
- Alexander KabiriQueens Village$268K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.